Drug profile

The FDA adverse-event record for Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid

34 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid. See the species affected, top reactions, and outcomes below.

34
adverse-event reports
85.3%
death-coded share
Cattle
most-reported species
26
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
29
Deaths Reported
85.3%
Death Rate

Active Ingredients

Clostridium Chauvoei Bacterin ToxoidClostridium Novyi Bacterin ToxoidClostridium Perfringens Type C Bacterin ToxoidClostridium Perfringens Type D Bacterin ToxoidClostridium Septicum Bacterin ToxoidClostridium Sordellii Bacterin Toxoid

Administration Routes

UnknownSubcutaneousIntramuscular

Species Affected

Cattle 34

Most Affected Breeds

Cattle (other) 19
Crossbred Bovine/Cattle 6
Cattle (unknown) 4
Aberdeen Angus 3
Charolais 1
Holstein-Friesian also known as Holstein 1

Most Reported Reactions

Death 26
Lack of efficacy - NOS 22
Depression 3
Anorexia 3
Necropsy performed 3
Bloody diarrhoea 2
Fever 2
Death by euthanasia 2
Lack of efficacy (bacteria) - NOS 2
Recumbency 1
NT - necrohemorrhagic enteritis 1
NT - ulcerative colitis 1

Outcome Breakdown

Died
28 (50.0%)
Outcome Unknown
12 (21.4%)
Recovered/Normal
7 (12.5%)
Ongoing
6 (10.7%)
Recovered with Sequela
2 (3.6%)
Euthanized
1 (1.8%)

Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid Adverse Event Insights

34 reports name Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid; 29 recorded a death outcome (85.3% of reported events, not a population-level mortality rate). Active ingredients: Clostridium Chauvoei Bacterin Toxoid, Clostridium Novyi Bacterin Toxoid, Clostridium Perfringens Type C Bacterin Toxoid, Clostridium Perfringens Type D Bacterin Toxoid, Clostridium Septicum Bacterin Toxoid. Administration routes: Unknown, Subcutaneous, Intramuscular.

By species: Cattle (34 reports). By breed: Cattle (other) (19), Crossbred Bovine/Cattle (6), Cattle (unknown) (4).

Leading clinical signs: Death (26), Lack of efficacy - NOS (22), Depression (3), Anorexia (3). Outcome, 56 coded reports: Died leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.